H. Lundbeck A/S
General ticker "HLUBF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $5.0B (TTM average)
H. Lundbeck A/S follows the US Stock Market performance with the rate: 26.4%.
Estimated limits based on current volatility of 0.2%: low 5.47$, high 5.49$
Factors to consider:
- Company pays dividends (irregularly): last record date 2026-03-20, amount 0.18$ (Y3.30%)
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.63$, 7.28$]
- 2026-12-31 to 2027-12-31 estimated range: [4.86$, 7.66$]
Financial Metrics affecting the HLUBF estimates:
- Positive: with PPE of 10.8 at the end of fiscal year the price was very low
- Positive: Operating cash flow per share per price, % of 14.49 > 12.98
- Positive: Operating profit margin, % of 26.05 > 18.65
- Negative: negative Industry operating cash flow (median)
- Negative: 0.75 < Interest expense per share per price, % of 1.60
- Positive: Inventory ratio change, % of 0.19 <= 0.80
- Negative: negative Industry operating income (median)
- Negative: 42.34 < Shareholder equity ratio, % of 46.11 <= 63.79
- Negative: Investing cash flow per share per price, % of -1.81 <= -0.65
Short-term HLUBF quotes
Long-term HLUBF plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | DKK19,912.00MM | DKK22,004.00MM | DKK24,295.84MM |
| Operating Expenses | DKK16,717.00MM | DKK18,734.00MM | DKK17,967.21MM |
| Operating Income | DKK3,195.00MM | DKK3,270.00MM | DKK6,328.63MM |
| Non-Operating Income | DKK-202.00MM | DKK449.00MM | DKK-1,851.80MM |
| Interest Expense | DKK54.00MM | DKK113.00MM | DKK539.77MM |
| R&D Expense | DKK3,457.00MM | DKK4,501.00MM | DKK4,687.36MM |
| Income(Loss) | DKK2,993.00MM | DKK3,719.00MM | DKK4,476.84MM |
| Taxes | DKK703.00MM | DKK576.00MM | DKK1,292.07MM |
| Net Income(Loss)* | DKK1,385.00MM | DKK3,016.00MM | DKK3,184.77MM |
| Stockholders Equity | DKK22,045.00MM | DKK25,010.00MM | DKK24,846.59MM |
| Inventory | DKK4,427.00MM | DKK3,983.00MM | DKK4,462.87MM |
| Assets | DKK37,407.00MM | DKK56,976.00MM | DKK53,889.66MM |
| Operating Cash Flow | DKK4,080.00MM | DKK3,326.00MM | DKK4,886.91MM |
| Capital expenditure | DKK501.00MM | DKK565.00MM | DKK552.75MM |
| Investing Cash Flow | DKK-498.00MM | DKK-15,286.00MM | DKK-609.62MM |
| Financing Cash Flow | DKK-2,085.00MM | DKK11,629.00MM | DKK-5,466.59MM |
| Earnings Per Share** | DKK1.40 | DKK3.04 | DKK3.21 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.